Current Report Filing (8-k)
April 20 2017 - 8:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 20, 2017
AGENUS INC.
|
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
000-29089
|
06-1562417
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
3 Forbes Road
Lexington, MA
|
02421
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
781-674-4400
N/A
(Former name or former address,
if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other Events.
Agenus Inc. (the “Company”)
announced today that the first patient has been dosed in the Company’s Phase 1/2 clinical trial of its anti-PD-1 antibody,
AGEN2034. The open-label, dose-escalation portion of the trial is designed to evaluate the safety and pharmacological activity
of AGEN2034 in patients with advanced solid tumors. Part 2 of the trial is planned to evaluate the recommended dose of AGEN2034
in patients with second line cervical cancer. Preliminary safety and efficacy data are expected to be available within the next
9-12 months.
AGEN2034 is an antagonist antibody targeting
programmed death 1, or PD-1. PD-1 is an inhibitory receptor expressed on activated T cells. When this receptor interacts with PD-L1
and/or PD-L2 molecules expressed on cancer cells, the T cells’ ability to kill cancer cells is neutralized. Therefore, blocking
PD-1 with AGEN2034 may allow T cells to recognize and kill tumor cells.
The full text of the press release issued
in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description of Exhibit
|
|
|
99.1
|
Press Release dated April 20, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: April 20, 2017
|
AGENUS INC.
|
|
|
|
|
By:
|
/s/ Christine M. Klaskin
|
|
|
Christine M. Klaskin
|
|
|
VP, Finance
|
EXHIBIT INDEX
Exhibit No.
|
Description of Exhibit
|
|
|
99.1
|
Press Release dated April 20, 2017.
|
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024